Heinz-Josef Lenz, MD, of the University of Southern California Norris Comprehensive Cancer Center, discusses the efficacy and safety of dabrafenib and trametinib in patients with BRAF V600E–mutated biliary tract cancer (Abstract 187).
Carl C. Schimanski, MD, PhD, of the Municipal Hospital Darmstadt, discusses phase II study findings on adjuvant immunotherapy with tecemotide after colorectal cancer liver metastasectomy (Abstract 480).
Jeffrey A. Meyerhardt, MD, MPH, of Dana-Farber Cancer Institute, discusses phase III study findings on S-1/oxaliplatin vs uracil and tegafur/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer (Abstract 484).
Andrew X. Zhu, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses phase II/III study findings on neoadjuvant chemotherapy with gemcitabine and S-1 vs upfront surgery for resectable pancreatic cancer (Abstract 189).
Manish A. Shah, MD, of NewYork–Presbyterian/Weill Cornell Medical Center, discusses phase III data on the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (Abstract 4).
Jonathan R. Strosberg, MD, of the Moffitt Cancer Center, discusses phase II study findings on pembrolizumab as a treatment for advanced neuroendocrine tumors (Abstract 190).
